Cytochrome P450 3A · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Cytochrome P450 3A shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P08684. Start with HIV infection, then reuse UniProt P08684 as the stable protein anchor across project notes and exports.
Start with HIV infection, then reuse UniProt P08684 as the stable protein anchor across project notes and exports.
Cytochrome P450 3A shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with HIV infection because it currently carries approved-linked support. Linked drugs include COBICISTAT, RITONAVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyCytochrome P450 3A4
Review this target as Cytochrome P450 3A, mapped to UniProt P08684. ChEMBL maps the protein component as Cytochrome P450 3A4. Sequence length is 503 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cytochrome P450 3A as ChEMBL target CHEMBL2364675, mapped to UniProt P08684. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Cytochrome P450 3A is the right protein anchor across sources, using UniProt P08684 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why HIV infection is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Cytochrome P450 3A |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P08684 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Cytochrome P450 3A4 |
| UniProt Accession | P08684 |
| Component Type | Protein |
| Sequence Length | 503 aa |
Cytochrome P450 3A4
Review this target as Cytochrome P450 3A, mapped to UniProt P08684. ChEMBL maps the protein component as Cytochrome P450 3A4. Sequence length is 503 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Cytochrome P450 3A shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block.
Start review with HIV infection because it currently carries approved-linked support. Linked drugs include COBICISTAT, RITONAVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL583090 | 8.92 | Ki | 1.2 | Preclinical |
| CHEMBL1136 | 8.62 | Ki | 2.4 | Approved |
| CHEMBL583093 | 8.28 | Ki | 5.3 | Preclinical |
| CHEMBL583091 | 8.25 | Ki | 5.6 | Preclinical |
| CHEMBL163 | 7.89 | Ki | 13.0 | Approved |
| CHEMBL583299 | 7.62 | Ki | 24.0 | Preclinical |
| CHEMBL583298 | 7.6 | Ki | 25.0 | Preclinical |
| CHEMBL163 | 6.85 | IC50 | 140.0 | Approved |
| CHEMBL3527048 | 6.8 | IC50 | 160.0 | Preclinical |
| CHEMBL269732 | 6.44 | Ki | 360.0 | Approved |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 34 | 5 | 5.9 |
| microsome format | 30 | 11 | 6.6 |
| protein format | 14 | 1 | 6.2 |
| cell-based format | 4 | 0 | — |
| tissue-based format | 1 | 0 | — |